Mabwell (Shanghai) Bioscience Future Growth
Future criteria checks 2/6
Mabwell (Shanghai) Bioscience is forecast to grow earnings and revenue by 47.5% and 73.3% per annum respectively. EPS is expected to grow by 47.5% per annum. Return on equity is forecast to be -47.9% in 3 years.
Key information
47.5%
Earnings growth rate
47.5%
EPS growth rate
Biotechs earnings growth | 34.8% |
Revenue growth rate | 73.3% |
Future return on equity | -47.9% |
Analyst coverage | Low |
Last updated | 26 May 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,847 | -131 | 9 | 62 | 5 |
12/31/2025 | 992 | -641 | -628 | -423 | 5 |
12/31/2024 | 335 | -919 | -861 | -993 | 5 |
3/31/2024 | 191 | -1,018 | -1,349 | -961 | N/A |
12/31/2023 | 128 | -1,053 | -1,283 | -783 | N/A |
9/30/2023 | 107 | -936 | -1,375 | -774 | N/A |
6/30/2023 | 107 | -945 | -1,479 | -777 | N/A |
3/31/2023 | 28 | -976 | -1,271 | -611 | N/A |
12/31/2022 | 28 | -955 | -1,264 | -719 | N/A |
9/30/2022 | 26 | -947 | -1,148 | -657 | N/A |
6/30/2022 | 20 | -853 | -932 | -550 | N/A |
3/31/2022 | 20 | -833 | -858 | -578 | N/A |
12/31/2021 | 16 | -770 | -640 | -422 | N/A |
9/30/2021 | 11 | -699 | -581 | -392 | N/A |
12/31/2020 | 5 | -643 | -646 | -515 | N/A |
12/31/2019 | 29 | -928 | -540 | -354 | N/A |
12/31/2018 | 37 | -225 | -380 | -156 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688062 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 688062 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 688062 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 688062's revenue (73.3% per year) is forecast to grow faster than the CN market (13.4% per year).
High Growth Revenue: 688062's revenue (73.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688062 is forecast to be unprofitable in 3 years.